Related Experiment Video
Updated: Mar 17, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
1.3K
Rheumatoid Arthritis Management: Emerging Drug Therapies and Innovations
Dushyant1, Smita Narwal1, Gurvirender Singh2
1Global Research Institute of Pharmacy, Radaur, Yamuna Nagar, Haryana, 135133, India.
Current Drug Targets
|March 15, 2026
Summary
New treatments for Rheumatoid Arthritis (RA) include targeted biologics and advanced drug delivery systems. These innovations aim to improve efficacy, reduce side effects, and enhance long-term disease management for patients.
Area of Science:
- Immunology
- Pharmacology
- Rheumatology
Background:
- Rheumatoid Arthritis (RA) is a chronic autoimmune disease causing joint inflammation and destruction.
- Genetic (e.g., HLA-DR1, HLA-DR4) and environmental factors contribute to RA pathogenesis.
- RA involves cytokine overproduction, autoantibodies, synovial inflammation, and joint damage.
Purpose of the Study:
- To review the latest advancements in Rheumatoid Arthritis management.
- Focus on new drug formulations, targeted biologics, and novel Drug Delivery Systems (DDS).
Main Methods:
- Systematic literature search of articles, trials, and patents on RA treatments.
- Focused review on biologic Disease-Modifying Anti-Rheumatic Drugs (biologic DMARDs), small-molecule inhibitors, personalized medicine, and DDS.
Main Results:
- Biologic DMARDs (e.g., TNF and interleukin inhibitors) have transformed RA management.
- Small-molecule inhibitors offer orally bioavailable treatment options.
- Advanced Drug Delivery Systems (ADI) enhance specificity, efficacy, and reduce toxicity; biomarker-directed therapy shows promise.
Conclusions:
- RA therapy is shifting towards biologics, personalized medicine, and advanced DDS.
- These approaches enable targeted action, reduced toxicity, and improved long-term outcomes.
- The integration of personalized medicine and DDS offers future solutions for enhanced patient care and quality of life.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
469
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
469
01:29Inflammatory Bowel Disease IV: Pharmacological Management
899
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
899
01:20Rheumatic Heart Disease IV: Nursing Management
426
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
426
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
702
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
702
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
639
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
639
01:28Drug Therapy
370
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
370